| Aligos Therapeutics is a clinical-stage biopharmaceutical company. Co. utilizes its proprietary oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens designed to achieve improved treatment outcomes. Co. has developed a portfolio of differentiated drug candidates for Chronic Hepatitis B, including a small molecule Capsid Assembly Modulator and oligonucleotides, each of which is designed against clinically validated targets in the Hepatitis B Virus life cycle. Co. is also exploring approaches towards boosting immune response with the use of small molecule antagonists of the PD1/PD-L1 interaction. We show 9 historical shares outstanding datapoints in our ALGS shares outstanding history coverage, used to compute ALGS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALGS market cap history over the course of time is important for investors
interested in comparing ALGS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALGS versus a peer is one thing; comparing
ALGS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALGS can fluctuate over the course of history.
With this page we aim to empower investors researching ALGS by allowing them to research the ALGS market cap history.